furosemide has been researched along with Nephrosis in 10 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Nephrosis: Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), a potent adenosine A1-receptor antagonist, on the nephrotic edema induced by puromycin aminonucleoside (PAN; 100 mg/kg, i." | 7.69 | Effects of KW-3902, an adenosine A1-receptor antagonist, on ascites volume in puromycin aminonucleoside (PAN)-induced nephrotic rats. ( Karasawa, A; Kusaka, H; Nagashima, K, 1995) |
| "A corticosteroid- and furosemide-induced excessive increase in proteinuria developed in a 34-year-old nephrotic patient with focal glomerulosclerosis." | 7.68 | Corticosteroid- and furosemide-induced increase in proteinuria in nephrosis. ( Fujisawa, M; Inariba, H; Inoue, T; Kanayama, Y; Negoro, N; Okamura, M; Takeda, T, 1990) |
| "We investigated the effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), a potent adenosine A1-receptor antagonist, on the nephrotic edema induced by puromycin aminonucleoside (PAN; 100 mg/kg, i." | 3.69 | Effects of KW-3902, an adenosine A1-receptor antagonist, on ascites volume in puromycin aminonucleoside (PAN)-induced nephrotic rats. ( Karasawa, A; Kusaka, H; Nagashima, K, 1995) |
| "A corticosteroid- and furosemide-induced excessive increase in proteinuria developed in a 34-year-old nephrotic patient with focal glomerulosclerosis." | 3.68 | Corticosteroid- and furosemide-induced increase in proteinuria in nephrosis. ( Fujisawa, M; Inariba, H; Inoue, T; Kanayama, Y; Negoro, N; Okamura, M; Takeda, T, 1990) |
| "Furosemide was extensively bound to urinary protein (19." | 1.27 | Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients. ( Berardi, RR; Hyneck, ML; Port, FK; Smith, DE, 1985) |
| " Its effect is dosage dependent." | 1.25 | [Pharmacological and toxicological properties of the saluretic xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylidide)]. ( Bahrmann, H; Leuschner, F; Neumann, W, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (80.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| LARIZZA, P | 1 |
| BRUNETTI, P | 1 |
| NENCI, G | 1 |
| COLI, L | 1 |
| KOENIGSTEIN, RP | 1 |
| Green, TP | 1 |
| Mirkin, BL | 1 |
| Kusaka, H | 1 |
| Nagashima, K | 1 |
| Karasawa, A | 1 |
| Leuschner, F | 1 |
| Neumann, W | 1 |
| Bahrmann, H | 1 |
| Inoue, T | 1 |
| Okamura, M | 1 |
| Negoro, N | 1 |
| Fujisawa, M | 1 |
| Inariba, H | 1 |
| Takeda, T | 1 |
| Kanayama, Y | 1 |
| Sjöström, P | 1 |
| Smith, DE | 1 |
| Hyneck, ML | 1 |
| Berardi, RR | 1 |
| Port, FK | 1 |
| Laragh, JH | 1 |
| Herrmann, GR | 1 |
| Ghiselli, RG | 1 |
10 other studies available for furosemide and Nephrosis
| Article | Year |
|---|---|
[CLINICO-THERAPEUTIC OBSERVATIONS AND RENAL FUNCTION TESTS WITH THE NEW DIURETIC, FUROSEMIDE].
Topics: Diuretics; Edema; Furosemide; Heart Diseases; Heart Failure; Hepatitis; Hypertension; Kidney Functio | 1964 |
[USE OF FUROSEMIDE (LASIX) IN GERIATRICS. CONTRIBUTION TO THE EVALUATION OF THE SO-CALLED DIABETOGENIC EFFECT OF SALIDIURETICS].
Topics: Diabetes Mellitus; Diuretics; Drug Therapy; Edema; Furosemide; Geriatrics; Hypertension; Liver Cirrh | 1965 |
Resistance of proteinuric rats to furosemide: urinary drug protein binding as a determinant of drug effect.
Topics: Animals; Diuresis; Female; Furosemide; Glomerular Filtration Rate; Models, Biological; Nephrosis; Ph | 1980 |
Effects of KW-3902, an adenosine A1-receptor antagonist, on ascites volume in puromycin aminonucleoside (PAN)-induced nephrotic rats.
Topics: Animals; Ascites; Diuretics; Edema; Furosemide; Male; Nephrosis; Purinergic P1 Receptor Antagonists; | 1995 |
[Pharmacological and toxicological properties of the saluretic xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylidide)].
Topics: Animals; Blood Glucose; Chlorides; Diuresis; Diuretics; Dogs; Dose-Response Relationship, Drug; Drug | 1975 |
Corticosteroid- and furosemide-induced increase in proteinuria in nephrosis.
Topics: Adult; Furosemide; Glomerulosclerosis, Focal Segmental; Humans; Male; Methylprednisolone; Nephrosis; | 1990 |
Mechanisms of reduced effects of loop diuretics in healthy volunteers and in patients with renal disease.
Topics: Adult; Diuresis; Diuretics; Drug Tolerance; Female; Furosemide; Humans; Kidney; Kidney Failure, Chro | 1988 |
Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients.
Topics: Adult; Dialysis; Female; Furosemide; Half-Life; Humans; Kinetics; Male; Middle Aged; Nephrosis; Osmo | 1985 |
Ethacrynic acid and furosemide.
Topics: Ethacrynic Acid; Furosemide; Heart Failure; Humans; Liver Cirrhosis; Nephrosis | 1968 |
Clinical experience with furosemide.
Topics: Adolescent; Adult; Aged; Ascites; Carbon Dioxide; Chlorides; Diabetes Complications; Diuresis; Edema | 1968 |